Previous 10 | Next 10 |
- Global Reliance on Spike Protein-Based Vaccines May Create Public Health Risks - - Omicron’s Many Mutations Occur in Regions Outside Those of IBIO-202’s Nucleocapsid Antigen - - Company Expecting Feedback from U.S. FDA on IBIO-202 in January - BRYAN...
New African Virus Variant Puts These Penny Stocks In The Spotlight Today What’s going on in the stock market today? Earlier this week, we were heading into the holiday nearing record-high levels. Countless penny stocks were red hot, and retail traders were reaping the rewards...
BRYAN, Texas, Nov. 17, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System ® , announced t...
iBio (NYSE:IBIO): Q1 GAAP EPS of -$0.04. Revenue of $0.21M (-48.8% Y/Y) misses by $0.29M. Press Release For further details see: iBio misses on revenue
- Adds First New Anti-cancer Target for Development in Partnership with RubrYc Therapeutics - - Initiates Research C ollaboration with UT Southwestern to Study Anti-fibrotics in Oncology - - Establishes Partnership for Development of Painless Intradermal Vaccine ...
BRYAN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System ® , today announced a resear...
iBio (NYSE:IBIO) is scheduled to announce FQ1 earnings results on Monday, November 15th, after market close. The consensus EPS Estimate is -$0.05 (flat Y/Y) and the consensus Revenue Estimate is $0.5M (+22.0% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downw...
BRYAN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System ® , announced t...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Though most of us would like to forget last year, the novel coronavirus pandemic continues to impact our lives. The wounds caused by the tragedies in our society are still present as businesses look to recover and employees...
iBio (NYSE:IBIO) acquired the manufacturing facility it previously operated under a lease, from two affiliates of Eastern Capital. The company also acquired the ~30% equity interest in iBio CDMO LLC, held by the Eastern Affiliates. As a result, the subsidiary and its intellectual property are...
News, Short Squeeze, Breakout and More Instantly...
– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio’s transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or th...
2024-05-28 07:30:05 ET Chardan Capital analyst issues BUY recommendation for IBIO on May 28, 2024 05:34AM ET. IBIO was trading at $2.19 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current analyst recommendations are : 1 - Hold recommenda...
Strengthened cash position with investment by healthcare specialist investors Expanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company...